Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Xin-Yun Huang
Weill Medical Coll of Cornell Univ, Department: Physiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novita
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Xin-Yun Huang and his spouse founded the company Novita which is a privately held biopharmaceutical company dedicated to developing drugs to prevent and treat cancer metastasis. In collaboration with WCM and pursuant to a Sponsored Research Agreement, Novita and Cornell have discovered, developed, and filed joint patent applications on a series of small-molecule fascin inhibitors. Cornell University and Novita each have joint ownership of this intellectual property. Cornell has licensed its share of its jointly owned intellectual property to Novita. Dr. Huang and his spouse have equity in Novita.
Dr. Huang’s research interests at WCM focus on tumor cell migration and tumor metastasis, both on the molecular mechanisms and the development of therapeutic agents inhibiting tumor cell migration and tumor metastasis. Dr. Huang’s NIH grant’s objective is to develop small molecule inhibitors to target tumor cell migration and invasion, which are critical steps in the process of tumor metastasis. WCM has determined that since Dr. Huang’s area of study involves investigating potential therapeutics for treatment of metastatic cancer, specifically investigating the mechanism action of fascin inhibitors, and because Dr. Huang and his spouse have equity in Novita, this creates a financial conflict of interest with Dr. Huang’s NIH grant (R01CA193815).
Targeting fascin to block tumor metastasis
This proposal investigates potential therapeutics for treatment of metastatic cancer. The spread or recurrence of cancer is every cancer patient's worst fear, but unfortunately there is currently no curative treatment for cancer once it has metastasized. Therefore, there is a tremendous need for new treatments for metastatic (advanced stage) cancer.
Filed on September 20, 2016.
Tell us what you know about Xin-Yun Huang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.